Marketing Communication
Bionics is biology-inspired engineering. It applies concepts and systems found in nature to the design of advanced medical devices. Companies in this area make devices including artificial heart valves, insulin pumps, pacemakers and joint replacements. Technological advances are improving the capabilities of these devices and promise to make far more possible. Think of brain chips that cure deafness, bioprinting that regenerates joints or exoskeletons that restore mobility.
VanEck Medical Robotics and Bionic Engineering UCITS ETF
- Bionic ETF allows to profit from a fast evolution
- High-tech healthcare that positively impacts people and planet
- Growing demand from a fast-ageing global population
CYBO
ETF Details
ETF Details
Basis-Ticker:CYBOISIN:IE0005TF96I9
TER:0.55%
AUM:$11.3 M (as of 06-02-2026)
SFDR Classification:Article 9
Lower risk
Typically lower rewardHigher risk
Typically higher reward1
2
3
4
5
6
7
Risks of a Bionic ETF: You may lose money up to the total loss of your investment due to the Main Risk Factors, such as Industry or Sector Concentration Risk and Liquidity Risks described below in the
KID
and the sales
prospectus
Evolving of the market is not guaranteed.
Experts anticipate there are four stages to the biomachine interface evolution.1 Below are some examples:
1 Source: McKinsey Global Institute.
Brain stimulation for Parkinson’s, neuroprosthetics for hearing, to brain activity monitoring to diagnose diseases.
Neuroprosthetics for sight, deep brain stimulation for Alzheimer’s, depression, and anxiety, to neuro priming for athletic performance.
From neuroergonomics to improve workplace design (e.g., reduce stress levels in the cockpit); to direct brain-to-device communication for paralyzed people.
From interpreting emotions through measured brain waves and enhancing sensory perception for consumer use to leveraging computers to augment the brain.
Why Invest in a Bionic ETF?
Bionics is a fast-expanding medical field set to fulfill a substantial need. The Bionic ETF by VanEck offers one of the few ways to invest in a diversified portfolio of companies.
Helping the Ageing Population
Source: UN population prospects.
Companies included in a Bionic ETF
Today the companies underlying this Fund specialize in a range of fields, from heart valves to medical implants and diabetes monitoring devices. They include Edwards Lifesciences, a leader in artificial heart valves; Medtronic, which makes insulin pumps and pacemakers; and Stryker Corp, known for its joint replacements. As the new interfaces between man and machine evolve, so will Bionic ETF’s holdings.
DexCom Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous...
DexCom, Inc. empowers people to take control of diabetes through innovative continuous...
Stryker Corp.
Stryker, one of the world’s leading medical technology companies...
Stryker, one of the world’s leading medical technology companies...
Medtronic Inc.
Medtronic Inc. is one of the world's market leaders in medical...
Medtronic Inc. is one of the world's market leaders in medical...
Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart...
Edwards Lifesciences is the global leader in the science of heart...
Zimmer Biomet Holdings, Inc.
The company specializes in developing, manufacturing and...
The company specializes in developing, manufacturing and...
Key Documents and Links
Main Risk Factors of a Medical Robotics ETF
The Fund’s assets may be concentrated in one or more particular sectors or industries. The Fund may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries.
The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.
Exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.
Please contact us for more information:
- Phone: +41 (0)44 562 40 65
- Email: [email protected]